April 26, 2024
When child psychiatrist Javeed Sukhera, MD, PhD, was a few years into his career, he found himself doing it all. “I was in a leadership role […]
April 26, 2024
TOPLINE: Findings from an echocardiographic study of patients with heart failure with preserved or mildly reduced ejection fraction treated with an atrial shunt have shed more […]
April 26, 2024
TOPLINE: In patients with non–small cell lung cancer (NSCLC) who have metastases to the brain only, definitive treatment to the primary site improved overall survival outcomes […]
April 26, 2024
Docket Number: FDA-2024-D-1461 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The Food and Drug Administration (FDA or Agency) is announcing the availability […]
April 26, 2024
TOPLINE: Delta wave activity disruption during sleep may be a useful metric to identify those at an increased risk for cardiovascular disease and cardiovascular mortality. METHODOLOGY: […]
April 26, 2024
Latest Update Clozapine Risk Evaluation and Mitigation Strategy (REMS) Advisory Committee Meeting 2024 April 25, 2024 – FDA will be hosting an in-person advisory committee meeting […]
April 26, 2024
DENVER — After working for decades in a field littered with promising but failed clinical trials, a prominent researcher in amyotrophic lateral sclerosis (ALS) has decided […]
April 26, 2024
The antidepressant properties of esketamine, a derivative of ketamine, have been the subject of numerous studies for several years. A nasal spray formulation is authorized under […]
April 26, 2024
DENVER — Unlike traditional antidiabetic therapies, which have never been associated with a significant reduction in stroke in a major trial, some of the newer drugs […]